The Onemytis® 2 is now available in the UK
I don’t think I’m overstating it to say this is the future of soft tissue veterinary surgery. It’s brilliant.”
Julian Hoad, Crossways Veterinary Group, West Sussex
Onemytis® 2 is a new type of electrosurgical instrument which is changing the face of soft tissue surgery. First launched in Italy in 2014, Onemytis® is widely used in Europe particularly for ENT, ophthalmology, dermatology and for most of the oncological surgeries. By using Airplasma® technology, the device is able to perform a wide range of surgical procedures with exceptionally high levels of precision at low temperatures.
The latest model, the Onemytis® 2, is now available in the UK. Even faster and more compact than the original it has specialist accessories for endoscopic and laparoscopic surgery and it can be easily upgraded as new software and accessories become available.
Vets across Europe are increasingly turning to Onemytis® for soft tissue surgery.
As well as being an effective tool for surgery, there is a growing body of evidence to show that Cold Atmospheric Plasma also:
Onemytis® 2 uses a new technology called Airplasma® which works by gas (in this case, air) ionization. Air is passed through a strong electromagnetic field at high voltage, releasing energy (plasma) which can vaporise tissue at low temperatures. It operates at a maximum temperature of 50° C as opposed to temperatures of more than 118° C reached in conventional electrosurgery.
The cutting edge of the electrode is extremely fine and does not touch the patient. Plasma is formed when it is between 1 and 2 mm away from the patient, depending on the power setting. This means the surgeon does not apply any pressure when creating an incision, furthering increasing the precision with which the device is used.
There is no need for an external gas source or a return plate because there is no build-up of electric current or heat within the patient’s body. The electrical current emitted by Onemytis® 2 is less than 2mA.
‘Clinical experience with cold plasma in the treatment of locally advanced head and neck cancer’, Metelmann, H-R. et al. Clinical Plasma Medicine 9, 2018
‘Plasma-activated medium (PAM) kills human cancer-initiating cells’, Ikeda J. et al Pathology International, 2017
‘Endothelial cell proliferation is enhanced by low-dose non-thermal plasma through fibroblast growth factor 2 release’, Kalghati, S. et al. Annals of Biomedical Engineering 38:3 2010
‘Cold atmospheric plasma (CAP) activates angiogenesis-related molecules in skin keratinocytes, fibroblasts and endothelial cells and improves wound angiogenesis in an autocrine and paracrine mode’, Arndt, S. et al. Journal of Dermatological Science 2018
‘Immunogenic potential of cold atmospheric plasma for the treatment of pancreatic cancer’, Van Loenhout, J. et al, Clinical Plasma Medicine 9, 2018
‘Potentiating anti-tumour immunity with physical plasma’, Bekeschus, S. et al Clinical Plasma Medicine 12, 2018
Talk to us if you are considering investing in lasers for the first time or think you could be doing more with them in your practice. We are here to help.